Enhancing the QUAlity and Transparency Of health Research

EQUATOR resources in German | Portuguese | Spanish

Blog Archives

04/02/2015 Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet 15/07/2013 Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis 12/07/2013 Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia 13/06/2013 Setting the bar in phase II trials: the use of historical data for determining “go/no go” decision for definitive phase III testing 28/01/2013 The CONSORT statement checklist in allergen-specific immunotherapy: a GA2LEN paper

Blog archives

Latest guest blogger

  • Why did we develop TIDieR-Placebo?

    The TIDieR reporting guideline helps authors fully report their interventions, so that they can be used by others. However, TIDieR only explicitly covers active interventions, not placebo controls. The developers of the new TIDieR-Placebo extension explain why it is needed Read More